SLC5A5 and neoplasm: VSV-IFNβ-NIS, a recombinant oncolytic VSV, can be safely administered intravenously (IV) to reach sites of metastatic disease and has been shown selectively replicate in and destroy tumor cells and activate an anti-tumor immune response [2].